SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

The summary for the SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional): This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and/or in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required
Federal Grant Title: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-19-047
Type of Funding: Grant
CFDA Numbers: 93.394, 93.395
CFDA Descriptions: Information not provided
Current Application Deadline: August 9th, 2019
Original Application Deadline: August 9th, 2019
Posted Date: April 8th, 2019
Creation Date: April 8th, 2019
Archive Date: September 14th, 2019
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: April 8th, 2019
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. see the funding announcement for eligibility details
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-047.html
Grant Announcement Contact
NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologi...
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Ca...
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate C...
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic...
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Ca...
Image-Guided Cancer Interventions (STTR [R41/R42])
An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44)
In Vivo Cancer Imaging Exploratory/Developmental Grants
More Grants from the National Institutes of Health
Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
NINDS Program Project Grant (P01 Clinical Trial Optional)
Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com